The Community Oncology Alliance (COA) recently formed a standing Biosimilars Committee, for which The Center for Biosimilars® advisory board member, Kashyap Patel, MD, a practicing medical oncologist at Carolina Blood and Cancer Care in South Carolina, was named chair alongside co-chairs immediate past president of COA, Jeff Vacirca MD, FACP, and Michael Diaz, MD, incoming
The Community Oncology Alliance (COA) recently submitted formal comments to the Centers for Medicare and Medicaid Services (CMS) regarding the Medicare Program International Pricing Index Model for Medicare Part B Drugs pre-proposed rule, also known as the IPI Model.
The Community Oncology Alliance (COA) has submitted formal comments to the Centers for Medicare and Medicaid Services (CMS) regarding the Medicare Program International Index Model for Medicare Part B Drugs, commonly known as the IPI Model.
While the Oncology Care Model (OCM) is likely not a sustainable mode for oncology care, it will probably inform what payment structure comes next, said Michael Kolodziej, MD, vice president, chief innovation officer, ADVI Health, Inc.
We are writing on behalf of the Part B Access for Seniors and Physicians (ASP) Coalition, which is committed to advancing life-saving innovation in the U.S. We are greatly concerned about a proposal by the Centers for Medicare & Medicaid Services (CMS) to implement an unprecedented, mandatory experiment affecting Medicare beneficiaries who take Part B-covered
A proposed 2019 rule change for services furnished under the Medicare Physician Fee Schedule (MPFS) is not going down well with oncologists. In July, the Centers for Medicare & Medicaid Services (CMS) issued the proposed change that would lower some payments for patient evaluation and maintenance (E/M) services.
Medicare cuts and budgetary adjustments are driving a Del Rio cancer treatment clinic into a possible closure. The facility, Rio Bravo Cancer and Blood, 1301 Ave. G, Del Rio, Texas, is the only one of its kind in this part of the state, and serves approximately 1,000 patients. Rio Bravo Cancer and Blood Practice Administrator,
Patient advocacy groups have objected swiftly to a proposal that would grant Medicare Part D health plans new liberty to reject or restrict certain protected-class drugs, which the plans have been required for more than a decade to cover.
Today, 35% of oncology drugs in the pipeline are oral, according to a recent report by the Community Oncology Alliance (COA). With the rise of oral oncolytic prescribing and development, more oncology practices are implementing in-office dispensing programs to provide a seamless treatment experience for patients.
Radiation oncologists are concerned about the possibility of mandatory participation in a radiation oncology demonstration after HHS Secretary Alex Azar indicated such a model was on the way. Ted Okon, executive director of the Community Oncology Alliance, said layering mandatory demonstrations on top of the voluntary Oncology Care Model doesn’t make much sense. The American